Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Underreporting of Adverse Drug Events: a Look into the Extent, Causes, and Potential Solutions
Ahmad Z. Al Meslamani
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 5, pp. 351-354
Open Access | Times Cited: 22

Showing 22 citing articles:

Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database
Robert Morris, Rahinatu Ali, Feng Cheng
Current Drug Targets (2024) Vol. 25, Iss. 7, pp. 454-464
Closed Access | Times Cited: 8
Adverse Reactions by Radiopharmaceuticals: Retrospective Analysis of the Portuguese National Pharmacovigilance System
Sara Martins, Ângelo Jesus, Ricardo Andrade, et al.
Annals of Pharmacotherapy (2025)
Open Access | Times Cited: 1
Transformers and large language models in healthcare: A review
Subhash Nerella, Sabyasachi Bandyopadhyay, Jiaqing Zhang, et al.
Artificial Intelligence in Medicine (2024) Vol. 154, pp. 102900-102900
Open Access | Times Cited: 6
Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study
Elena Fountzilas, Sofia Karageorgopoulou, Georgios Karakatsoulis, et al.
ESMO Real World Data and Digital Oncology (2025) Vol. 7, pp. 100095-100095
Closed Access
Descriptive analysis of the national drug adverse events (AEs) database in Lebanon
Rita Karam, Sarah Reda El Sayed, Aya Ibrahim, et al.
Journal of Pharmaceutical Policy and Practice (2025) Vol. 18, Iss. 1
Open Access
Discrepancies in adverse event reporting for ketamine trials
J N Rea, Adam Khan, Nicholas Boyne, et al.
British Journal of Anaesthesia (2025)
Closed Access
Adverse Drug Event Reporting Among Women: Uncovering Disparities in Underserved Communities
Ahmad Z. Al Meslamani
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 5, pp. 543-545
Open Access | Times Cited: 3
Pharmacovigilance in Vaccines: Importance, Main Aspects, Perspectives, and Challenges—A Narrative Review
Katharine Valéria Saraiva Hodel, Bianca Sampaio Dotto Fiuza, Rodrigo Souza Conceição, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 6, pp. 807-807
Open Access | Times Cited: 3
Why are outcome-based drug safety research studies scarce? Insights into operational challenges and potential solutions
Ahmad Z. Al Meslamani
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 2, pp. 145-148
Open Access | Times Cited: 2
The pharmacists’ interventions after a Drug and Therapeutics Committee (DTC) establishment during the COVID-19 pandemic
Amira B. Kassem, Ahmad Z. Al Meslamani, Dina H. Elmaghraby, et al.
Journal of Pharmaceutical Policy and Practice (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 2
Disparities in drug safety practices in developing nations: focusing on underlying factors and implications for global health
Ahmad Z. Al Meslamani, Derar H. Abdel‐Qader, Amira B. Kassem, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 4, pp. 393-397
Open Access | Times Cited: 1
The long-term clinical impact of digital endpoints and biomarkers in data collection
Ahmad Z. Al Meslamani
Expert Review of Pharmacoeconomics & Outcomes Research (2024) Vol. 24, Iss. 6, pp. 697-699
Open Access
Stakeholder perspectives on the need for professional education and competence in pharmacovigilance in Zambia: A cross-sectional survey
Aubrey Chichonyi Kalungia, Michelo Banda, Moses Mukosha, et al.
Pharmacy Education (2024) Vol. 24, Iss. 1, pp. 364-381
Open Access
Pharmacovigilance of Radiopharmaceuticals: Challenges and Opportunities
Sara Martins, Ângelo Jesus, Ana Martín- Suárez
Journal of Pharmacy Technology (2024) Vol. 40, Iss. 5, pp. 257-259
Closed Access
A Narrative Review of Pharmacovigilance: Report of Adverse Drug Reactions in Mexico
Miguel Luján Estrada, Aivle Libertad Hernández Caamaño, Karla Roman Flores
IntechOpen eBooks (2024)
Closed Access
Disparities in Hereditary Angioedema In An Urban Medical District
John Trickett, David A. Khan, Jeffrey Chambliss
The Journal of Allergy and Clinical Immunology In Practice (2024)
Closed Access
Author response to ‘Clarification on the incidence and sex-specificity of sexual dysfunction as an adverse event of CGRP-targeting medications’
Linda Al‐Hassany, Deirdre M. Boucherie, E. G. M. Couturier, et al.
Cephalalgia (2024) Vol. 44, Iss. 10
Closed Access
Machine learning to predict adverse drug events based on electronic health records: a systematic review and meta-analysis
Qiaozhi Hu, Jiafeng Li, Xiaoqi Li, et al.
Journal of International Medical Research (2024) Vol. 52, Iss. 12
Open Access
Pharmacovigilance in Australia – how do adverse event reports from clinicians contribute to medicine and vaccine safety?
Deborah Greenbaum, Stephanie G. Cheung, Claire Turner, et al.
Australian Prescriber (2024) Vol. 47, Iss. 6, pp. 186-191
Closed Access
Barriers and Facilitators on Pharmacovigilance Practice Among Pharmacists in Metro Manila, Philippines
Rogie Royce Carandang, Justin Gabriel Gumop‐as, Salve Regina Andoloy, et al.
Pharmacoepidemiology and Drug Safety (2024) Vol. 33, Iss. 12
Closed Access
The impact of CFTR modulators on mental health: Moving the field forward
Anna M. Georgiopoulos, Emma M. Tillman
Journal of Cystic Fibrosis (2024)
Closed Access
The causes for underreporting of adverse events and action priorities
Muhammad Aaqib Shamim, Aravind P. Gandhi, Prakasini Satapathy, et al.
Journal of Medicine Surgery and Public Health (2023) Vol. 1, pp. 100011-100011
Open Access | Times Cited: 1
Page 1

Scroll to top